Evidence map›Paper›PMID 37916173›Full record

ArticleFrontiers in oncology2023

Characterization of a cohort of metastatic lung cancer patients harboring

Lucía Notario, Marc Cucurull, Gabriela Cerdà, Carolina Sanz, Enric Carcereny, Ana Muñoz-Mármol, Ainhoa Hernández, Marta Domènech, Teresa Morán, Montse Sánchez-Céspedes and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Lucía NotarioMedical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Marc CucurullMedical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Gabriela CerdàMedical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Carolina SanzPathology Department, Germans Trias i Pujol University Hospital (HUGTiP), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Enric CarcerenyMedical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Ana Muñoz-MármolPathology Department, Germans Trias i Pujol University Hospital (HUGTiP), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Ainhoa HernándezMedical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Marta DomènechMedical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Teresa MoránMedical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Montse Sánchez-CéspedesCancer Genetics Group, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain.
Marta CostaBadalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Jose-Luis MatePathology Department, Germans Trias i Pujol University Hospital (HUGTiP), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Anna EsteveStatistics Department, Catalan Institute of Oncology (ICO)-Badalona, Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Maria SaigíMedical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, Germans Trias i Pujol University Hospital (HUGTiP), Badalona-Applied Research Group in Oncology (B-ARGO), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain.
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESInstitut Català d'Oncologia · ESJosep Carreras Leukaemia Research Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 20% of lung adenocarcinomas harbor activating mutations at

Indexed as

immunotherapyKRASlung adenocarcinomanon-small cell lung cancerPD-L1

Identifiers

PMID37916173
PMCPMC10616300
OpenAlexW4387704662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.